An international group of researchers is teaming up to develop a myeloma treatment that harnesses the cancer-killing abilities of…
Articles by Marisa Horak, MS
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the experimental therapy enzomenib (DSP-5336) as a…
More than 40% of patients in a Phase 1 clinical trial of myeloma treatment cevostamab responded to the drug,…
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Eli Lilly’s experimental medication olomorasib as…
Most myeloma patients taking Tecvayli (teclistamab-cqyv) were alive and free from disease progression two years after starting treatment,…
A large, late-stage clinical trial testing an immunotherapy in people with gynecological cancers is recruiting participants ahead of schedule,…
A study linked high expression of the protein desmoglein-2 (DSG2) to lower survival in people with myeloma. Data suggest…
A combination treatment using two Johnson & Johnson immunotherapies outperformed standard care regimens in reducing the risk of disease…
The experimental anticancer therapy CR-001 was generally well tolerated in a first-in-human clinical trial that tested several doses in 11…
Maintenance therapy for myeloma can be stopped after two years without raising the risk of disease progression or death,…